Shutterstock
Across the biopharmaceutical industry, many have expressed concern about the protracted timelines for drug development, which on average are getting longer when most stakeholders insist the time to market (TTM) needs to be shorter. Nowhere is this clearer than with new modalities, particularly cell therapies that are often personalised and manufactured starting from a patient’s own cells.